Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8212255 | 0.87 | KDM4E (0.39) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL21798323 | 0.77 | KDM4E (0.39) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL25520674 | 0.76 | USP2 (0.48) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL373746 | 0.74 | USP2 (0.46) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL15605706 | 0.74 | USP2 (0.46) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL16028605 | 0.71 | KDM4E (0.43) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL6485137 | 0.71 | KDM4E (0.43) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL21798362 | 0.70 | HTR5A (0.30) | — | |
| SCHEMBL21798392 | 0.70 | TRPA1 (0.32) | — | |
| SCHEMBL21798084 | 0.70 | KDM4E (0.36) | USP2TSHRKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466821-B2 | Antiviral pyridopyrazinedione compounds | NOVARTIS AG (CH) | 2025-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466821-B2 | Antiviral pyridopyrazinedione compounds | ZC3HAV1, IL5, TYMP | USP2 4211/4885TSHR 4291/4885KDM4E 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.